Synedgen, Inc. will present recent study results on the successful application of the company’s novel polymer PAAG for treating Cystic Fibrosis. The data is compiled in two posters entitled “PAAG decreases viscosity and Improves Transportability of Cystic Fibrosis Mucus In Situ” and “Novel Biopolymer Mucolytic PAAG Prevents and Treats Biofilms…
News
The Great Strides event, a fundraiser associated with the Cystic Fibrosis Foundation, has become the largest national fundraiser advocating for cystic fibrosis (CF), held through monthly initiatives and with the support of families, donors, and friends. This month, those honored by the event are Jen and Justin Grady,…
More and more people are turning to daring, extraordinary feats to call much-needed public attention to orphan diseases such as cystic fibrosis (CF), a debilitating and life-threatening hereditary condition that affects about 70,000 individuals throughout the world. A pair of brothers have recently committed themselves…
E. coli fluorescence Undergraduate students from the University of Dundee in Scotland are working on harnessing the power of laboratory-cultured, non-pathogenic E. coli to help cystic fibrosis patients fend off other harmful bacteria that could infect the lungs. Respiratory infections pose a serious threat to…
Data supporting a promising, new treatment for Cystic Fibrosis (CF) developed by Verona Pharma will be presented for the first time at the 28th Annual North American Cystic Fibrosis Conference (NACFC) in Atlanta, Georgia on October 9-11, 2014. Verona Pharma’s key molecule, RPL554, is currently being evaluated in a…
Dr. Stuart Elborn When it comes to formulating new and improved antibacterial treatments, scientists are in a race against the time it takes for today’s bacteria to mutate into more harmful, resistant strains. Even with today’s technology and advanced research practices, emerging pharmaceutical…
Young adults and children with cystic fibrosis in the United States have better lung function than those who live in the United Kingdom, despite the fact that both countries have well-developed healthcare systems. Differences in lung function may be a result of differences in healthcare structure, according to the…
2014 has been a year highlighted by a steady stream of compelling stories about young people with cystic fibrosis (CF) bearing witness to how a desire to live life to the fullest and lead an active, healthy lifestyle can overcome the daunting challenges and ominous realities of the disease. Joining…
Leerink Partners, a specialty investment bank in the field of healthcare, recently extended an invitation to Insmed Incorporated, the biopharmaceutical company behind a highly promising liposomal amikacin formulation to treat Pseudomonas aeruginosa infections in patients with cystic fibrosis (CF), to participate in a Rare Disease…
One of the pressing concerns physicians have with patients diagnosed with cystic fibrosis (CF) is their increased susceptibility to respiratory infections along with greatly decreased lung clearance. A condition that manifests quite similarly to CF is primary ciliary dyskinesia (PCD), a hereditary condition that impairs lung…
Your CF Community
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.